Financial Toxicity and Quality of Life in Patients With TGCT

Completed

Conditions studied: Testicular Neoplasm

In brief

This is a cross-sectional, observational study employing validated questionnaires to investigate financial toxicity in subjects with testicular germ cell tumors (TGCT). As background, TGCTs are the most common malignancies among men from age 15-35. Treatment is highly curative, but often consists of intensive multi-cycle chemotherapy with significant potential for physical toxicity. The treatment course itself is disruptive and long term physical and mental health consequences can increase risk for financial toxicity. Thus, we aim to study financial toxicity in both patients with TGCT actively receiving treatment and in TGCT survivors. There will be two separate cohorts: Cohort 1 will consist of subjects with recently diagnosed TGCT who will undergo multi-agent, multi-cycle chemotherapy and Cohort 2 will consist of subjects who have completed chemotherapy and are long-term survivors.

Key facts

Study ID

NCT04531709

Run by

The University of Texas Health Science Center at San Antonio

People needed

24

Starts

2023-03-01

Expected to finish

2025-02-04

Last updated by the study team

2025-07-14

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Age > 18 years of age
• Patients with histologically or clinically confirmed germ cell tumor.
• Completed treatment for germ cell tumor with multicycle (> 2 cycles) / multiagent chemotherapy.
• Within years 1-5 of surveillance since Day 1 of last cycle of chemotherapy
• Signed informed consent

You may not qualify if…

• Long-term survivors
• Patients undergoing active chemotherapy
• Patients who did not complete 1st line chemotherapy.

Where it is running

• Mays Cancer Center — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.